Tralokinumab studie. Feb 1, 2025 · Tralokinumab-ldrm injection is used alone or in combination with other medicines (eg, topical corticosteroids) to treat moderate to severe atopic dermatitis in patients who have been treated with topical medicines that did not work well or who cannot use topical treatment. Tralokinumab is a fully human IgG4 monoclonal antibody used to treat moderate to severe atopic dermatitis. Tralokinumab sold under the brand names Adtralza (EU/UK) and Adbry (US) among others, is a human monoclonal antibody used for the treatment of atopic dermatitis. Adbry (tralokinumab-ldrm) is a biologic drug approved by the FDA for people ages 12 and older with moderate to severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies used on the skin (topical therapies) or when those therapies are not advisable. The T-helper cytokine IL-13 is thought to play a key role in the pathogenesis of atopic dermatitis. Tralokinumab, also known as Adtralza®, is a treatment for moderate to severe atopic eczema (also known as atopic dermatitis) in adults and children aged 12 years and older. . Recent studies suggest IL-13 to be the most abundant cytokine in atopic dermatitis skin lesions with its levels having a direct correlation to severity of disease. May 19, 2025 · Tralokinumab is used to treat moderate-to-severe eczema (atopic dermatitis) in adults and children aged 12 years and older that is not responding well to prescription topical eczema treatments or in those who cannot use topical treatments. Tralokinumab (Adtralza ®) is a human IgG4 monoclonal antibody being developed by LEO Pharma for the treatment of atopic dermatitis. ADBRY® (tralokinumab-ldrm) injection is a prescription medicine used to treat people 12 years of age and older with moderate-to-severe atopic dermatitis (eczema) that is not well controlled with prescription therapies used on the skin (topical), or who cannot use topical therapies. Tralokinumab is a type of biologic drug called a monoclonal antibody. Medscape - Atopic dermatitis dosing for Adbry (tralokinumab), frequency-based adverse effects, comprehensive interactions, contraindications, pregnancy & lactation schedules, and cost information. ADBRY ® (tralokinumab-Idrm) injection is indicated for the treatment of moderate-to-severe atopic dermatitis in patients aged 12 years and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. ADBRY® (tralokinumab-ldrm) injection is a prescription medicine used to treat people 12 years of age and older with moderate-to-severe atopic dermatitis (eczema) that is not well controlled with prescription therapies used on the skin (topical), or who cannot use topical therapies. [3][5] Tralokinumab targets the cytokine interleukin 13. uhpmtx kxrl aylba rtaw iwq oabu laox exsyv glyp jmm

Tralokinumab studie. [3][5] Tralokinumab targets the cytokine interleukin 13.